ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
Status:
Completed
Trial end date:
2019-06-18
Target enrollment:
Participant gender:
Summary
This Phase 2, multicenter, randomized study will evaluate the safety, tolerability and
efficacy of ATI-501 for the treatment of Alopecia Areata (AA), Alopecia Universalis (AU) or
Alopecia Totalis (AT) in adult subjects.